Neogen Delivers 4.3% Core Growth in Q4, Sets FY2027 Outlook

summarizeSummary

Neogen reported Q4 FY2026 revenue of $225.3 million, with core growth of 4.3%—its best since FY2023—and issued FY2027 guidance for revenue of $880–$885 million and Adjusted EBITDA of $180–$182 million.

check_boxKey Events · Earnings and Guidance · NEOG

• Q4 Core Growth Hits 4.3%

  Total Q4 revenue reached $225.3 million, underpinned by core growth of 4.3%—the strongest pace of FY2026. Food Safety led the way with core growth of 5.8%, the segment's best showing since FY2023.

• Adjusted EBITDA Margin Expands

  Cost-saving initiatives and a favorable mix lifted Q4 Adjusted EBITDA to $45.4 million, expanding the margin to 20.2% from 18.0% a year ago.

• FY2027 Guidance Issued

  Management set FY2027 revenue guidance at $880–$885 million and Adjusted EBITDA at $180–$182 million, implying core growth of approximately 3%.

• Petrifilm Transition on Track

  The company expects to begin manufacturing sellable Petrifilm product in November 2026, with the first fully validated SKU slated for completion by the end of August 2026.

auto_awesomeAnalysis · NEOG · Life Sciences

Driven by a 5.8% increase in Food Safety, Neogen posted its highest quarterly core growth since FY2023. Adjusted EBITDA margins expanded to 20.2%, and the company introduced FY2027 guidance of $880–$885 million in revenue and $180–$182 million in Adjusted EBITDA. The Petrifilm manufacturing transition remains on schedule for November 2026, while the $160 million genomics sale to Zoetis is expected to close by mid-FY2027, with proceeds earmarked for debt reduction. Together, these results and forward indicators point to strengthening operational momentum after a difficult stretch.